Fig. 6
O2-enhancing PDT/chemotherapy of CPCCM with laser irradiation (CPCCM + L). A CLSM images of MDA-MB-231 cells with CPCCM (50 μg/mL) treatment at 2, 4, 6, 8 h. B Live/dead cell staining of CS-1 (5 μg/mL), Ce6 (2.5 μg/mL), CPM, CPCM, and CPCCM (50 μg/mL). C Viability of MDA-MB-231 cells treated with CPCCM (50 μg/mL) under 660 nm laser irradiation (200 mW). D ROS analysis of CS-1 (5 μg/mL), Ce6 (2.5 μg/mL), CPM, CPCM, and CPCCM (50 μg/mL) under normoxia or hypoxia. E The effect of CP@CS-1, CPCM + L, and CPCCM + L (50 μg/mL) treatment on ROS induction. Data were shown as mean ± SD, n = 3. ANOVA was used to assess statistical significance, ***p < 0.001